We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

38 hedge funds and large institutions have $84.1M invested in Spyre Therapeutics in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

96% more capital invested

Capital invested by funds: $42.9M → $84.1M (+$41.2M)

23% more funds holding

Funds holding: 31 → 38 (+7)

0.12% more ownership

Funds ownership: 1.91% → 2.03% (+0.12%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
38
Holders Change
+7
Holders Change %
+22.58%
% of All Funds
0.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
16
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.81M
2
Jennison Associates
Jennison Associates
New York
+$807K
3
Renaissance Technologies
Renaissance Technologies
New York
+$505K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$478K
5
DZ Bank
DZ Bank
Germany
+$473K

Top Sellers

Rank Fund Capital Flow
1
DCM
DAFNA Capital Management
California
-$1.89M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$85K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$72K
4
Macquarie Group
Macquarie Group
Australia
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$158K – – –
DS
27
DRW Securities
Illinois
$128K – – –
Goldman Sachs
28
Goldman Sachs
New York
$118K +$86K +476 New
SLG
29
Stanley-Laman Group
Pennsylvania
$118K +$86.4K +478 New
Squarepoint
30
Squarepoint
New York
$105K +$76.6K +424 New
BCPEM
31
Bain Capital Public Equity Management
Massachusetts
$95K +$69.4K +384 New
Bank of America
32
Bank of America
North Carolina
$74K +$3.25K +18 +6%
Morgan Stanley
33
Morgan Stanley
New York
$73K +$31.8K +176 +145%
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$59K +$21.1K +117 +98%
Barclays
35
Barclays
United Kingdom
$32K +$23.1K +128 New
Federated Hermes
36
Federated Hermes
Pennsylvania
$8K +$5.6K +31 New
IA
37
IFP Advisors
Florida
$3K – – –
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$2K +$1.45K +8 New
DCM
39
DAFNA Capital Management
California
– -$1.89M -13,984 Closed
Jacobs Levy Equity Management
40
Jacobs Levy Equity Management
New Jersey
– -$85K -628 Closed
Bank of New York Mellon
41
Bank of New York Mellon
New York
– -$72K -530 Closed
Macquarie Group
42
Macquarie Group
Australia
– -$9K -70 Closed
1
2

SYRE Hedge Fund Activity: Q1 2018 in Review

38 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2018, worth a combined $84.1M — up 96% from $42.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new SYRE positions and 4 closed out — a net gain of 7 holders — while 16 added to existing stakes and 0 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.81M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1.89M sold.

  • 38 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2018, up from 31 in Q4 2017.
  • Funds reported $84.1M of Spyre Therapeutics stock for Q1 2018, up 96% quarter-over-quarter.
  • 11 funds opened new Spyre Therapeutics positions in Q1 2018 and 4 closed out, a net change of +7 holders.
  • The largest Spyre Therapeutics buyer in Q1 2018 was Adage Capital Partners, an estimated $1.81M added.
  • The largest Spyre Therapeutics seller in Q1 2018 was DAFNA Capital Management, an estimated $1.89M sold.

Based on aggregated 13F filings for Q1 2018.